@article{Kennedy_N-2021_45548,
title = {Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab},
author = {Kennedy, N. and Goodhand, J. and Bewshea, C. and Nice, R. and Chee, D. and Lin, S. and Chanchlani, N. and Butterworth, J. and Cooney, R. and Croft, N. and Hart, A. and Irving, P. and Kok, K. and Lamb, Christopher A. and Limdi, J. and MacDonald, J. and McGovern, D. and Mehta, S. and Murray, C. and Patel, K. and Pollok, R. and Raine, T. and Russell, R. and Selinger, C. and Smith, P. and Bowden, J. and McDonald, T. and Lees, C. and Sebastian, S. and Powell, N. and Ahmad, T.},
month = {mar},
year = {2021},
abstract = {OBJECTIVE: Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.},
pages = {865-875},
volume = {70},
issue = {5},
journal = {Gut},
publisher = {BMJ Publishing Group},
url = {http://dx.doi.org/10.1136/gutjnl-2021-324388},
}
